Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07226622 · ClinicalTrials.gov registry record
Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial
A clinical trial of Wilson Disease, sponsored by Prime Medicine.
- Recruiting
- Registry status
- 30
- Enrollment target
- 7
- Study locations
NCT07226622: Recruiting study of Wilson Disease, sponsored by Prime Medicine.
NCT07226622 is a study of Wilson Disease that is actively recruiting participants, run by Prime Medicine. The registered enrollment target is 30 participants, below the 119-participant average among 4 other Wilson Disease trials with a reported enrollment target (75% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07226622, a study of Wilson Disease, is actively recruiting participants, sponsored by Prime Medicine.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 7
- Study locations
Study Summary
The aim of this study is to inform and improve future clinical trials in Wilson Disease (WD) by better understanding how patients with WD are living with and managing the disease, and by identifying key factors that shape their decisions to participate in clinical research.
Primary Outcome
This is a survey created by Prime Medicine. Survey answers are reported on both a scale and in open-ended response; the purpose of the survey is to better understand the patient's disease experience, current treatment and adherence, copper in diet and lifestyle, and gauge interest in a gene editing clinical study. No calculations with score values will be conducted.
Conditions Studied
Study Locations (7)
California
- University of California Los Angeles Medical Center - Los Angeles
- University of California Davis Health - Sacramento
Connecticut
- Yale New Haven Hospital - New Haven
Illinois
- Northwestern University - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- University of Michigan Medicine - Ann Arbor
Texas
- American Research Corporation - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-12-29 |
| Est. Completion | 2027-12 |
What NCT07226622 shows while recruiting
NCT07226622 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 119-participant average among 4 other Wilson Disease trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Wilson Disease appearing as the primary indexed condition, and to 0 interventions.
NCT07226622 lists 7 locations in 6 states (California, Connecticut, Illinois).
Frequently Asked Questions
What is clinical trial NCT07226622 about?
NCT07226622 is a clinical study titled "Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial". The aim of this study is to inform and improve future clinical trials in Wilson Disease (WD) by better understanding how patients with WD are living with and managing the disease, and by identifying key factors that shape their decisions to participate in clinical research.
What is the current status of trial NCT07226622?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2025-12-29. Estimated completion is 2027-12.
What conditions does trial NCT07226622 study?
This clinical trial studies the following conditions: Wilson Disease.
Who is sponsoring clinical trial NCT07226622?
This trial is sponsored by Prime Medicine, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07226622 being conducted?
This trial has 7 study locations across California, Connecticut, Illinois, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wilson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Natural History of Wilson Disease
RECRUITING
-
Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study
RECRUITING
-
A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease
ACTIVE NOT RECRUITING · Phase 1
-
The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI